Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373272 | 0.92 | TGFBR1 (0.65) | TGFBR1MAPK14PRKD1MTORRIPK2 | |
| SCHEMBL373659 | 0.88 | TGFBR1 (0.64) | TGFBR1MAPK14PRKD1MTORRIPK2 | |
| SCHEMBL373274 | 0.84 | TGFBR1 (0.68) | TGFBR1MAPK14PRKD1MTORRIPK2 | |
| SCHEMBL373624 | 0.83 | TGFBR1 (0.68) | TGFBR1MAPK14RIPK2ACVR1BADORA2B | |
| SCHEMBL373673 | 0.80 | TGFBR1 (0.62) | TGFBR1MAPK14PRKD1MTORRIPK2 | |
| SCHEMBL373192 | 0.80 | TGFBR1 (0.66) | TGFBR1MAPK14PRKD1MTORRIPK2 | |
| SCHEMBL373723 | 0.80 | TGFBR1 (1.00) | TGFBR1MAPK14PRKD1 | |
| SCHEMBL373273 | 0.76 | TGFBR1 (1.00) | TGFBR1MAPK14PRKD1 | |
| SCHEMBL373383 | 0.75 | TGFBR1 (0.66) | TGFBR1MAPK14RIPK2ACVR1BADORA2B | |
| SCHEMBL373888 | 0.73 | TGFBR1 (0.37) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885MAPK14 2025/4885PRKD1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.